



Nest Activity

Nest Activity allows researchers to stay up to date with the progress of their review, track engagement through [Synthesis](#) view counts and, if a [Dual Screening mode](#) is in use, view [Kappa Statistics/Interrater Reliability](#) for reviewers.



View Activity & Contributions

View nest activity in a specified time period: the last week, month, year, or all time. You can also select activity in a specific module from the dropdown to view in the graphical format or actions in the individual modules are displayed in the columns next to user IDs:




You may notice the numbers listed in some of the columns don't add up to the number of studies in the nest. This is because Activity tracks the individual steps taken in each module to get a more comprehensive overview of each users performance in the nest. For example, "Tagged: 113" doesn't refer to 113 studies tagged, rather 113 tags total




were applied by this user to a number of studies.

View Nest Workflow

In the workflow section you can view the overall progress in the nest in a visual format (Study Flow) and in a numerical format (Completion). When hovering over different sections in Study Flow, the associated numbers and %s will be displayed. In the following case, the Excluded section was hovered over indicating 77 records were excluded, which is 52.7% of all studies. Clicking on this will direct you to Study Inspector, which will apply the appropriate filter automatically and display all the excluded studies for your review.



In Completion, the exact numbers for modules completed and those that remain incomplete are displayed all at once (see the same figure of 77 excluded studies highlighted below). Similar to Study Flow, clicking on these numbers again directs you to Study Inspector to view those particular studies.



Note: unlike in the Activity box, Workflow displays numbers at the study-level. i.e. the number of studies included, excluded, tagged completely etc.

View Nest Engagement

Nest outputs can be configured to be public or private in admin settings. If your nest is set to public, these measures approximate engagement with the data and visuals of Synthesis Home, QLS, QNS and Manuscript and/or Dashboard.



You can discuss the progress of a Nest with the [Comments](#) feature.



Living systematic reviews undergo revisions and updating. For such reviews, you can expect to find an activity pattern with multiple peaks corresponding to the initial round, as well as subsequent updates.

Overall Module Progress

To get a snippet of overall progress in the Screening, Tagging, MA Extraction and Critical Appraisal modules, you can refer to the progress bars displayed on the main module page in the top right:

NESTED

KNOWLEDGE

Screening: Standard Modes: COVID-19

98 / 146

Nest Home

Activity

Settings

Literature Search

Other Sources

Duplicate Review

Search Exploration

Screening

Tagging

MA Extraction

Critical Appraisal

Study Inspector

Synthesis

Dashboard Editor

Abstract Editor

Export

Abstract

Full Text

Supplements

Related Reports

Suemori, 2021

A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome.

Severe fever with thrombocytopenia syndrome (SFTS) is a bunyavirus infection with high mortality. Favipiravir has shown effectiveness in preventing and treating SFTS virus (SFTSV) infection in animal models. A multicenter non-randomized, uncontrolled single arm trial was conducted to collect data on the safety and the effectiveness of favipiravir in treatment of SFTS patients. All participants received favipiravir orally (first-day loading dose of 1800 mg twice a day followed by 800 mg twice a day for 7-14 days in total). SFTSV RT-PCR and biochemistry tests were performed at designated time points. Outcomes were 28-day mortality, clinical improvement, viral load evolution, and adverse events (AEs). Twenty-six patients were enrolled, of whom 23 were analyzed. Four of these 23 patients died of multi-organ failure within one week (28-day mortality rate: 17.3%). Oral favipiravir was well tolerated in the surviving patients. AEs (abnormal hepatic function and insomnia) occurred in about 20% of the patients. Clinical symptoms improved in all patients who survived from a median of day 2 to day10. SFTSV RNA levels in the patients who died were significantly higher than those in the survivors (p = 0.0029). No viral genomes were detectable in the surviving patients a median of 8 days after favipiravir administration. The 28-day mortality rate in this study was lower than those of the previous studies in Japan. The high frequency of hepatic dysfunction as an AE was observed. However, it was unclear whether this was merely a side effect of favipiravir, because liver disorders are commonly seen in SFTS patients. The results of this trial support the effectiveness of favipiravir for patients with SFTS.

Population/Problem

Intervention

Outcome

Your Keywords

Keywords

Bibliographic fields

Edit

Navigation

Back

Skip

Screening

Full Text Review

P(Inclusion): 0.77

Upload Full Text

Exclude:

Search Reasons

Select Reason

Not an RCT of a drug of interest

Protocol or Methods article

Systematic Review or Meta-analysis

Editorial, comment, or opinion article

Not related to COVID-19

Update or guidelines article

Qualitative review of existing research

Include:

Include

Tagging

Comments (0)

History

These numbers refer to the number of records fully adjudicated (Screening) and marked “Complete” (Tagging, MA Extraction and Critical Appraisal).

From:

<https://wiki.nested-knowledge.com/> - **Nested Knowledge**

Permanent link:

<https://wiki.nested-knowledge.com/doku.php?id=wiki:autolit:utilities:activity>

Last update:

2023/10/11 12:29